Navigation Links
Viagra May Aid Those With Lung Fibrosis
Date:5/18/2010

Breathing improved for some taking sildenafil marketed as Revatio, study finds

TUESDAY, May 18 (HealthDay News) -- People with a serious lung disease that causes progressive scarring of the lung tissue might get some relief from sildenafil, the drug used in Viagra, a new study finds.

The disease, called idiopathic pulmonary fibrosis, causes the lungs to become increasingly thick and stiff, reducing the ability to breathe. There's no known cause, and there's little in the way of treatment, researchers say. Most people with the disease live just three to five years after diagnosis.

"There are about 150,000 patients in the United States and about 5 million worldwide with the disease," said lead researcher, Dr. David A. Zisman, from the Sansum Clinic in Santa Barbara, Calif. He cited Jerry Lewis, Evel Knievel and Robert Goulet as celebrities who had the disease, which he said has "no proven therapy, except lung transplantation, and survival is quite limited."

His research team decided to try treatment with sildenafil because the disease usually causes constriction of the blood vessels in the lungs, and sildenafil expands these vessels, Zisman said.

They randomly assigned 180 men and women with advanced pulmonary fibrosis to take 20 milligrams of sildenafil (sold as Revatio) or a placebo for 12 weeks; Viagra is sold in dosages starting at 25 milligrams. They found little difference in the main point being assessed, with 10 percent of those taking sidenafil and 7 percent of the others recording a 20 percent or greater improvement in the distance they could walk in six minutes.

However, some people taking sildenafil were able to breathe more easily and did show an improvement in their quality of life, the researchers found.

A report on the study, which was funded in part by Pfizer, which markets Revatio, was published online May 18 in the New England Journal of Medicine to coincide with a presentation on the findings that is slated to be held at the American Thoracic Society annual meeting, in Denver.

"It seems like this approach is an interesting way to provide these patients with improvement in dyspnea [shortness of breath] and quality of life, which hasn't been seen in patients with advanced idiopathic pulmonary fibrosis," Zisman said.

However, he said, people with the disease should not rush out to try sildenafil. "These findings offer a ray of hope to treat these patients," Zisman said. "We just have to fine-tune it."

Mishka Michon, chief executive of the Coalition for Pulmonary Fibrosis, said that "although the sildenafil trial didn't meet its primary endpoint, we're encouraged by the fact that there was a demonstration of symptomatic relief for some patients."

Because there are no current therapies that offer people with this disease a better quality of life, he said, "this news is particularly meaningful for our patients who experience incredibly difficult and unrelenting symptoms."

Zisman theorized that testing sildenafil on people with earlier stages of the disease might improve results. Higher doses might also improve the response, he said.

"This opens many doors to try exploring different approaches to treat these patients," Zisman said.

In the long run, he said, the goal in treating the disease may be to turn it into a chronic but livable condition, Zisman said. Rather than concentrating on finding ways to stop its progression, targeting the blood vessels in the lungs could lead to many other possibilities for treatment, he noted.

"In the future, we are going to see our patients treated like patients with cancer -- that is, several drugs to target different mechanisms of the disease," Zisman said. "We are going to end up treating these patients with a number of agents that would not only make a difference in quality of life and dyspnea, but also in functional capacity and survival."

In another study being presented at the same meeting, Japanese researchers found that inhaled N-acetylcysteine (NAC) preserves lung function in some people with idiopathic pulmonary fibrosis, when compared with people given no treatment.

"This novel study provides encouraging evidence to pursue the potential of an efficacious treatment with NAC for patients with the early stage of idiopathic pulmonary fibrosis," lead researcher Dr. Sakae Homma, a professor of respiratory medicine at the Toho University School of Medicine in Tokyo, said in a news release from the American Thoracic Society.

More information

The U.S. National Heart, Lung and Blood Institute has more on idiopathic pulmonary fibrosis.



SOURCES: David A. Zisman, M.D., Sansum Clinic, Santa Barbara, Calif.; Mishka Michon, chief executive, Coalition for Pulmonary Fibrosis, San Jose, Calif.; May 18, 2010, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. UAB study examines hearing loss, Viagra use
2. Study Explores Possibility of a Female Viagra
3. Taking Viagra Wont Spur Risky Sexual Behavior
4. Survey Finds Those Over 50 Are Less Stressed
5. Fibromyalgia affects mental health of those diagnosed and their spouses, study finds
6. Tapping away desire for those favorite foods and snacks
7. S.A. Lifeline Foundation Offers New and Improved Website for Those with Pornography Addictions
8. Health care reform important even to those who want new law repealed
9. New Book Offers Final Answer to 'What's for Dinner?' for People with Diabetes and Those Who Love Them
10. Dealing With Those All-Too-Public Tantrums
11. Those Who Enjoy Life More Likely to Be Happy at Work
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... 2017 , ... On Saturday, October 21, the Health & Wellness Center at ... raise money for the American Heart Association Heart Walk. Teams of up to 10 ... to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
Breaking Medicine Technology: